Answers are grounded in this paper and cite their sources.
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive motor neuron degeneration, with pathological mechanisms involving protein aggregation, impaired proteostasis, neuroinflammation, complement activation, and axonal dysfunction. Clusterin (CLU) is a multifunctional chaperone involved in extracellular protein quality control, complement regulation, stress responses, cell survival, and lipid homeostasis. Although CLU has been extensively investigated in Alzheimer’s disease, its pathogenic roles in ALS remain incompletely defined. Increasing evidence suggests that CLU may link several pathological processes relevant to ALS. Altered CLU expression has been reported in the motor cortex, spinal cord, cerebrospinal fluid (CSF), and plasma of ALS patients, although its expression differs between central and peripheral compartments. CLU can interact with aggregation-prone proteins and contribute to their clearance and protection against proteotoxicity. CLU also modulates complement-mediated neuroinflammation and influences motor neuron survival and axonal regeneration. These findings suggest potential roles for CLU as both a biomarker and a modulator of ALS pathogenesis. This review summarizes the structural characteristics and biological functions of CLU and discusses its roles in protein homeostasis, complement activation, neuroinflammation, motor neuron injury, and axonal regeneration in ALS. We further discuss the potential and limitations of CLU as a biomarker and therapeutic target and highlight priorities for future mechanistic and translational studies.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: